1
|
de Sousa FG, Queiroz FSF, Muzzi RAL, Veado JCC, Beier SL. Systemic Arterial Hypertension and Factors Associated with Blood Pressure Dysregulation in Companion Animals. Vet Sci 2025; 12:453. [PMID: 40431546 PMCID: PMC12115512 DOI: 10.3390/vetsci12050453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2025] [Revised: 04/28/2025] [Accepted: 05/07/2025] [Indexed: 05/29/2025] Open
Abstract
Systemic arterial hypertension (SAH), characterised by a persistent increase in BP beyond the reference values for the species, is a concerning and detrimental clinical condition. The aim of this manuscript is to present the state of the art on SAH in companion animals, including the different types of hypertension, diagnostic and therapeutic approaches, and the factors associated with its occurrence, such as the role of stress. It also discusses the benefits and challenges related to the measurement process. SAH is categorised into types based on the underlying cause: situational, secondary, and idiopathic (the least frequently observed). The situational type occurs when stress is the primary factor, such as during veterinary visits, contact with other animals, or in cases of 'white coat syndrome'. If the stressor is removed, BP values tend to normalise. The most common type of SAH is the secondary form, which is associated with an underlying condition, such as renal, cardiac, endocrine, or neurological diseases, or a combination of these. Diagnosing SAH is a challenging task for many veterinarians due to factors related to handling the animal, managing the equipment, and interpreting the results. Consequently, many professionals either take inaccurate measurements or misinterpret the results, often prescribing antihypertensive medications prematurely or unnecessarily. Despite being a well-standardised and well-documented process, challenges persist. Treatment often involves antihypertensive drugs, either alone or in combination, alongside management of the underlying causes, when present. Therefore, BP values should be obtained correctly, with clinical-therapeutic decisions carefully aligned with the factors that may influence them.
Collapse
Affiliation(s)
- Felipe Gaia de Sousa
- Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais—UFMG, Belo Horizonte 31620-295, MG, Brazil; (F.G.d.S.); (F.S.F.Q.); (J.C.C.V.)
| | - Fabiana Silva Fádel Queiroz
- Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais—UFMG, Belo Horizonte 31620-295, MG, Brazil; (F.G.d.S.); (F.S.F.Q.); (J.C.C.V.)
| | - Ruthnéa Aparecida Lázaro Muzzi
- Department of Veterinary Medicine, Faculty of Animal Science and Veterinary Medicine, Federal University of Lavras—FZMV/UFLA, Lavras 37200-900, MG, Brazil;
| | - Júlio César Cambraia Veado
- Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais—UFMG, Belo Horizonte 31620-295, MG, Brazil; (F.G.d.S.); (F.S.F.Q.); (J.C.C.V.)
| | - Suzane Lilian Beier
- Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais—UFMG, Belo Horizonte 31620-295, MG, Brazil; (F.G.d.S.); (F.S.F.Q.); (J.C.C.V.)
| |
Collapse
|
2
|
Morita S, Mochizuki Y, Kondo T, Matsuda Y, Ohmori T, Yoshimura A, Fukushima R. Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease. Front Vet Sci 2025; 12:1570349. [PMID: 40370820 PMCID: PMC12075874 DOI: 10.3389/fvets.2025.1570349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2025] [Accepted: 04/11/2025] [Indexed: 05/16/2025] Open
Abstract
Introduction In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension. Methods This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg). Results Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups. Discussion It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.
Collapse
Affiliation(s)
- Shohei Morita
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Youhei Mochizuki
- Faculty of Veterinary Medicine, Okayama University of Science, Okayama, Japan
| | - Takahiro Kondo
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Yasuyoshi Matsuda
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Takahiro Ohmori
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Aritada Yoshimura
- Animal Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Ryuji Fukushima
- Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan
| |
Collapse
|
3
|
Huang JH, Lourenço BN, Coleman AE. The renin-angiotensin-aldosterone system in kidney diseases of cats and dogs. Vet J 2025; 309:106287. [PMID: 39672318 DOI: 10.1016/j.tvjl.2024.106287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 12/04/2024] [Accepted: 12/04/2024] [Indexed: 12/15/2024]
Abstract
The renin-angiotensin-aldosterone system (RAAS) has a well-established key pathophysiologic role in kidney diseases, and pharmacotherapy targeting this system is a mainstay of treatment of affected human beings, cats, and dogs. Several studies have evaluated the circulating RAAS in animals with spontaneous or experimentally induced kidney diseases. Evidence supporting the activation of this system has been demonstrated in some - but not all - studies and individuals, and the interindividual variability in circulating RAAS markers is high. Advances over the last few decades have expanded our understanding of the system, which now includes the existence of a counterbalancing "alternative" RAAS and tissular renin-angiotensin systems (RASs), the latter regulated independently of the circulating endocrine RAAS. The local RAS in the kidney, termed the intrarenal RAS, is currently recognized as an important regulator of kidney function and mediator of kidney disease. In general, information on the intrarenal RAS is lacking in cats and dogs with kidney diseases; however, existing limited data suggest its activation. Despite the inconsistent evidence for circulating RAAS activation in chronic kidney diseases, RAAS inhibitors have proven effective for the treatment of its common comorbidities, systemic arterial hypertension and renal proteinuria, in both cats and dogs. Further research of the circulating RAAS, the intrarenal RAS, and the interplay between these systems in the context of kidney diseases in companion animals might contribute to the development or refinement of future treatment strategies.
Collapse
Affiliation(s)
- Jane Hc Huang
- Department of Small Animal Medicine and Surgery, University of Georgia, College of Veterinary Medicine, Athens 30601, USA
| | - Bianca N Lourenço
- Department of Small Animal Medicine and Surgery, University of Georgia, College of Veterinary Medicine, Athens 30601, USA.
| | - Amanda E Coleman
- Department of Small Animal Medicine and Surgery, University of Georgia, College of Veterinary Medicine, Athens 30601, USA
| |
Collapse
|
4
|
Diabetes Mellitus and the Kidneys. Vet Clin North Am Small Anim Pract 2023; 53:565-580. [PMID: 36854633 DOI: 10.1016/j.cvsm.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
The pathomechanisms implicated in diabetic kidney disease in people are present in dogs and cats and, in theory, could lead to renal complications in companion animals with long-standing diabetes mellitus. However, these renal complications develop during a long period, and there is little to no clinical evidence that they could lead to chronic kidney disease in companion animals.
Collapse
|
5
|
Zhan L, Wang X, Zhang Y, Zhu G, Ding Y, Chen X, Jiang W, Wu S. Benazepril hydrochloride protects against doxorubicin cardiotoxicity by regulating the PI3K/Akt pathway. Exp Ther Med 2021; 22:1082. [PMID: 34447475 PMCID: PMC8355712 DOI: 10.3892/etm.2021.10516] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 07/08/2021] [Indexed: 02/05/2023] Open
Abstract
Doxorubicin (DOX) stimulates the generation of reactive oxygen species, thereby impairing mitochondrial functions. Angiotensin-converting enzyme inhibitors (ACEIs) have been identified to exhibit protective effects on cardiovascular diseases. The present study aimed to test the hypothesis that an ACEI benazepril hydrochloride (HCl) may protect against DOX-induced cardiotoxicity. The DOX injury model was established using rat embryonic cardiac myoblast cells (H9c2 cell line) treated with DOX in vitro. H9c2 cells were treated with benazepril-HCl, DOX or a mixture of DOX and benazepril-HCl to measure the activities of myocardial enzymes including lactate dehydrogenase (LDH), superoxide dismutase, catalase and glutathione peroxidase, in addition to the concentration of malondialdehyde in the culture medium. Cells without any treatment were used as a control. DOX treatment increased the levels of activity of myocardial enzymes in H9c2 cells compared with those in the untreated control cells. Additionally, co-treatment with benazepril-HCl significantly reduced the levels of apoptosis occurring due to DOX-mediated cellular damage. The mechanistic experiment revealed that pretreatment with benazepril-HCl counteracted the DOX-induced oxidative stress and suppressed the activation of apoptosis via the PI3K/Akt signaling pathway. By contrast, an Akt inhibitor (MK2206) inhibited the protective effects of benazepril-HCl against DOX-induced H9c2 cell injury, as revealed by increased LDH release in H9c2 cells. These results suggested that benazepril-HCl may potentially be administered as an adjuvant for DOX in long-term clinical use.
Collapse
Affiliation(s)
- Lan Zhan
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Xiangxiu Wang
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Yanjing Zhang
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Guonian Zhu
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Yu Ding
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Xuemei Chen
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Wei Jiang
- Molecular Medicine Research Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| | - Sisi Wu
- Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
| |
Collapse
|
6
|
Ward JL, Chou YY, Yuan L, Dorman KS, Mochel JP. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease. J Vet Intern Med 2021; 35:2102-2111. [PMID: 34387901 PMCID: PMC8478030 DOI: 10.1111/jvim.16236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 07/22/2021] [Accepted: 07/22/2021] [Indexed: 12/02/2022] Open
Abstract
Background Angiotensin‐converting enzyme inhibitors (ACEIs) are commonly prescribed in dogs, but the ideal dosage is unknown. Hypothesis/Objectives In dogs with cardiac disease, a dose‐response relationship exists for ACEIs with respect to long‐term outcome. Animals One hundred forty‐four dogs with cardiac disease, 63 with current or prior congestive heart failure. Methods Retrospective medical record review. Cox proportional hazards models were used to determine variables associated with 2‐year survival or survival from first‐onset congestive heart failure (CHF). Results Median initial ACEI dosage was 0.84 (interquartile range [IQR], 0.56‐0.98) mg/kg/day, and 108/144 (75%) of dogs received q12h dosing. No clinically relevant changes in renal function test results, serum electrolyte concentrations, or blood pressure occurred between initial prescription of ACEI and first reevaluation (median, 14 days later). In univariable analysis, higher ACEI dose was associated with increased survival from first‐onset CHF (P = .005), and within the subgroup of dogs in CHF at the time of ACEI prescription, higher ACEI dose was associated with improved survival at 2 years (P = .04). In multivariable analysis, q12h dose frequency of ACEI (hazard ratio [HR], 0.30; 95% CI, 0.10‐0.88; P = .03) and higher serum potassium concentration at visit 1 (HR, 0.39; 95% CI, 0.16‐0.97; P = .04) were predictive of 2‐year survival. The ACEIs were well‐tolerated, with only 8/144 (5.6%) dogs having ACEI dose decreased or discontinued because of adverse effects. Conclusions and Clinical Importance Twice daily dose frequency might optimize the cardioprotective benefit of ACEIs.
Collapse
Affiliation(s)
- Jessica L Ward
- Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA
| | - Yen-Yu Chou
- Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA
| | - Lingnan Yuan
- Department of Statistics, Iowa State University, Ames, Iowa, USA.,Department of Biomedical Sciences, SMART Pharmacology, Iowa State University, Ames, Iowa, USA
| | - Karin S Dorman
- Department of Statistics, Iowa State University, Ames, Iowa, USA.,Department of Genetics, Development and Cell Biology, Iowa State University, Ames, Iowa, USA
| | - Jonathan P Mochel
- Department of Biomedical Sciences, SMART Pharmacology, Iowa State University, Ames, Iowa, USA
| |
Collapse
|
7
|
Evaluation of the progression of non-azotemic proteinuric chronic kidney disease in dogs. Res Vet Sci 2021; 138:11-18. [PMID: 34090202 DOI: 10.1016/j.rvsc.2021.05.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 05/20/2021] [Accepted: 05/22/2021] [Indexed: 11/23/2022]
Abstract
Proteinuria is a recognized risk factor for progression of canine chronic kidney disease (CKD). However, the prognosis of non-azotemic proteinuric CKD in dogs has been studied only to a limited extent. Moreover, the degree to which proteinuria should be decreased to delay CKD progression remains unknown. The purposes of this study were (1) to identify factors associated with disease progression and (2) to investigate the degree of proteinuria, albuminuria, and blood pressure during the course of treatment associated with the progression using time-averaged urine protein:creatinine ratio (UPC) and urine albumin:creatinine ratio (UAC) in canine non-azotemic proteinuric CKD. Twenty-one dogs with non-azotemic proteinuric CKD were included in the study. High UPC and UAC were associated with CKD progression (P < .05). Time-averaged high UPC and UAC were significantly related to progression (P < .05). The cutoff values of these time-averaged parameters for predicting the progression were 4.1 and 2.0, respectively. In dogs with non-azotemic proteinuric CKD, more severe proteinuria and albuminuria were associated with progression. The present study suggests that because UPC ≥ 4.1 and UAC ≥ 2.0 during treatment were associated with a faster progression of non-azotemic proteinuric CKD, therapeutic intervention is warranted.
Collapse
|
8
|
Xie XJ, Li CQ. Chrysophanol Protects Against Acute Heart Failure by Inhibiting JNK1/2 Pathway in Rats. Med Sci Monit 2020; 26:e926392. [PMID: 33044948 PMCID: PMC7566230 DOI: 10.12659/msm.926392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 07/24/2020] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Acute heart failure (AHF) usually requires urgent therapy. Myocardial damage, oxidative stress, and inflammation are major components in the pathology of AHF. This study was designed to investigate the effects of chrysophanol on AHF. MATERIAL AND METHODS Sprague-Dawley rats were injected with isoprenaline hydrochloride to construct AHF rat models. AHF rats were treated with normal saline (negative control), chrysophanol, the combination of chrysophanol and SP600125, or benazepril (positive control) using sham rats as blank controls. Echocardiography, histological staining, and enzyme activity analysis were performed to assess the heart functions and myocardial damage. Effects on apoptosis, oxidative stress (OS), and inflammation were evaluated by biochemical analysis, TUNEL staining, and ELISA. RESULTS Chrysophanol improved the parameters of cardiac functions and alleviated the myocardial damage accompanied by the reduction of creatine kinase and lactate dehydrogenase activity. Meanwhile, chrysophanol inhibited the myocardial apoptosis along with the upregulation of Bcl-2 and downregulation of Bax and cleaved caspase-3. AHF-induced abnormal changes of OS parameters (MDA, GPx, CAT, SOD) and inflammatory markers (IL-6, IL-1ß, TNF-alpha, IFN-γ) were alleviated by chrysophanol. Benazepril treatment showed similar results with chrysophanol, while the addition of SP600125 enhanced the chrysophanol-mediated protection effects in AHF rats. Western blot analysis demonstrated that chrysophanol inhibited the phosphorylation of JNK1/2 and its upstream/downstream factors. CONCLUSIONS Chrysophanol improved cardiac functions and protected against myocardial damage, apoptosis, OS, and inflammation by inhibiting activation of the JNK1/2 pathway in AHF rat models. These finding indicate that chrysophanol may be a promising approach for treatment of AHF.
Collapse
Affiliation(s)
- Xiao-Jiang Xie
- Department of Cardiology, Inner Mongolia Medical University Affiliated Hospital, Hohhot, Inner Mongolia, P.R. China
| | - Chang-Qing Li
- Department of Cardiology, Inner Mongolia Medical University Affiliated Hospital, Hohhot, Inner Mongolia, P.R. China
| |
Collapse
|